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Abstract 
Objective: To determine the effect of atorvastatin on rat heart failure after myocardial in-
farction and to investigate the underlying mechanism of atorvastatin-mediated myocardium 
protection. 
Methods: Thirty-eight rats were randomly divided into three groups: a heart failure model 
group (model group), a heart failure plus atorvastatin treatment group (atorvastatin group) 
and a sham-surgery group (control group). The rat heart failure model was established by 
ligation of the left anterior descending of coronary arteries (LADs). Changes in hemodynamics 
parameters were recorded after the final drug administration. Plasma brain natriuretic peptide 
(BNP)  concentration  was  determined  by  enzyme-linked  immunosorbent  assay  (ELISA). 
Histological diagnosis was achieved by hematoxylin and eosin (H&E) and Masson's trichrome 
staining. The expressions of 78kDa glucose-regulated protein 78 (GRP78), caspase-12 and 
C/EBP homologous protein (CHOP, also known as GADD153) in myocardial cells and cul-
tured cardiac myocytes were examined by Western blot. Terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) was used to evaluate myocardial cell apoptosis, and 
flow cytometry was performed to examine the cell apoptosis of cultured cardiac myocytes. 
Results: In the atorvastatin group, myocardial cells were lined up more orderly and myo-
cardial fibrosis level was decreased compared to the model group. The expressions of GRP78, 
caspase-12 and CHOP in myocardial cells were decreased in atorvastatin group. Moreover, in 
the atorvastatin-treated group the cell apoptosis rate was reduced and the endoplasmic re-
ticulum (ER) stress was activated in response to heart failure and angiotensin II(Ang II) 
stimulation.  
Conclusions: By down-regulating GRP78, caspase-12 and CHOP expressions in myocardial 
cells in rat heart failure after myocardial infarction, atorvastatin treatment decreased the 
apoptosis of myocardial cells, suggesting the possible mechanism by which atorvastatin func-
tions in protecting against heart failure. 
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Introduction 
Heart  failure  (HF)  after  myocardial  infarction 
(MI) is a common clinical syndrome with high mor-
bidity and mortality [1]. It has been suggested that HF 
is closely correlated with cardiac remodeling, as the 
dysfunction  of  cardiac  myocyte  activates  numerous 
signaling pathways which ultimately lead to remod-
eling [1]. Although a variety of known factors are in-
volved in the development and progression of HF, the 
mechanism of HF after MI is still poorly understood.  
Increased  cardiomyocyte  apoptosis  has  been 
observed in HF after MI both in animal models and in 
humans [2, 3]. Additionally, oxidative stress plays a 
significant role in tissue necrosis and reperfusion in-
jury during this process [4]. It has been demonstrated 
that subcellular organelle endoplasmic reticulum (ER) 
greatly developed in hypertrophic and failing hearts, 
implying  ER  dysfunction  may  contribute  to  heart 
failure [5]. 
 In response to various cellular stresses, ER stress 
response  (ERSR)  is  activated  to  protect  and  repair 
stress-induced  cellular  disorder  by  inducing  cell 
apoptosis. Three signaling pathways are involved in 
cell apoptosis mediated through the ERSR: the C/EBP 
homologous protein (CHOP), the caspase-12, and the 
c-Jun NH2-Terminal kinase (JNK) [6-8]. In addition, as 
a chaperone in the ER, glucose regulated protein 78 
(GRP78) plays a crucial role in the regulation of the ER 
dynamic equilibrium, and is a marker for ERSR [9]. 
Recent studies showed that ERSR may lead to cardiac 
myocyte apoptosis during the progression of HF [10, 
11]. Under such circumstances, the inhibition of ERSR 
may  suppress  the  activation  of  ERSR-induced  cell 
apoptosis signaling pathway, so that heart function 
will be improved [12]. 
Hydroxymethylglutaryl  coenzyme  A  reductase 
inhibitors (statins) therapy has been demonstrated to 
benefit  patients  with  HF,of  either  ischemic  or 
non-ischemic  causes,  by  improving  endothelial 
function, inhibiting inflammatory cytokines, potenti-
ating nitric oxide (NO) synthesis, restoring impaired 
autonomic function, reversing pathologic myocardial 
remodeling, and inhibiting apoptosis of myochardial 
cells  [13].  The  application  of  atorvastatin,  a  clinical 
statin  drug,  in  patients  with  non-ischemic  HF  im-
proved  left  ventricular  ejection  fraction  (LVEF)  and 
attenuated adverse left ventricular remodeling [14]. In 
addition,  atorvastatin  depressed  inflammatory  pro-
cess in patients with HF [15]. Nevertheless, the func-
tional  role  of  atorvastatin  in  myocardial  protection 
after  MI,  and  whether  the  impacts  of  atorvastatin 
treatment-induced apoptosis inhibition are mediated 
by  interfering  with  ERSR, has  not  yet  been  clearly 
illustrated. 
In the present study, an in vivo rat MI model and 
angiotensin II (Ang II) - stimulated cardiac myocytes 
in vitro were established for evaluating the potential 
effect of  atorvastatin on myocardial protection. Our 
results imply that atorvastatin inhibited apoptosis of 
myocardial cells in rat HF after MI by reducing the 
ERSR. This study therefore revealed the possible un-
derlying mechanism by which atorvastatin functions 
in myocardial protection. 
 
Materials and Methods 
Reagents 
Atorvastatin  was  purchased  from  Pfizer  (New 
York  City,  NY,  USA).  The  enzyme-linked  immuno-
sorbent assay (ELISA) kit for assessing the level of rat 
brain  natriuretic  peptide  (BNP)  was  obtained  from 
Adlitteram Diagnostic Laboratories (USA). Antibod-
ies against Caspase-12, GRP78, CHOP and the termi-
nal deoxynucleotidyl transferase dUTP nick end  la-
beling  (TUNEL)  -staining  kit  were  purchased  from 
Roche Applied Science (South San Francisco, Califor-
nia, USA). Ang II was obtained from Sigma (St. Louis, 
MO, USA).  
Establishment of the rat MI model 
Wistar rats (female) weighing 200 to 220 g were 
obtained  from  the  Center  for  Laboratory  Animals, 
Medical College, Jilin University (Jilin, China). Ani-
mals  were  randomly  divided  into  an  untreated  HF 
group  (model,  n=15),  a  HF  model  +atorvastatin 
treatment group (atorvastatin treatment group, n=16) 
and a sham opration group (control, n=7). 
To establish the HF model after MI, diethyleth-
er-anesthetized rats were fixed on the operating table. 
The thoracic cavity was opened to expose the heart, 
and the left coronary arteries (LADs) were ligated. In 
the control group, the sutures were passed under the 
LADs without ligation. The thoracic cavity was closed 
immediately  after  the  heart  was  returned.  Animals 
were housed routinely following surgery.  
Four weeks after surgery, rats in the atorvastatin 
treatment  group  received  10  mg/kg/d  atorvastatin 
for  4  weeks.  Experiments  were  performed  4  weeks 
after the start of the drug administration period (i.e., 8 
weeks  after  surgery).  All  experimental  procedures 
were approved by the Animal Ethics Committee of 
Jilin University. Int. J. Med. Sci. 2011, 8 
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Hemodynamic examination 
After  the  final  drug  administration,  rats  were 
anesthetized  with  3%  sodium  pentobarbital  (30 
mg/kg)  by  intraperitoneal  injection.  Catheters  were 
inserted  into  the  left  ventricle  through  the  right 
common  carotid  artery.  Changes  in  hemodynamics 
parameters,  including  the  left  ventricular 
end-diastolic  pressure  (LVEDP),  the  left  ventricular 
systolic pressure (LVSP), the maximal rate of rise in 
blood  pressure  in  the  ventricular  chamber  (+dP/dt 
max) and the maximal rate of decline in blood pressure 
in the ventricular chamber (-dP/dtmax) were measured 
and  recorded  by  an  8-channel  polygraph  system 
(RM-6000). 
Evaluation of the plasma BNP concentration 
Rats were euthanized  and blood samples were 
collected from  the abdominal  aorta.  The blood  se-
rum was  separated  and  the  plasma  BNP  concentra-
tion was determined by  ELISA according to  manu-
facturer’s instructions (Adlitteram Diagnostic Labor-
atories, USA). 
Histological diagnosis 
Myocardium tissues in the left ventricle of sacri-
ficed  rats  (approximately  2  mm in  thickness) 
were removed.  Samples  were  fixed in 4% pre-cooled 
paraformaldehyde for 72 h and embedded in paraffin 
for  histological  studies.  Paraffin-embedded  tissues 
were sectioned into slices ~5 μm thick. Sections were 
stained  with  hematoxylin  and  eosin  (H&E).  Mas-
son's trichrome stain was  performed to assess  myo-
cardial fibrosis. Images were visualized under an op-
tical microscope at ×200 magnification. 
Terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL)  
The cell apoptosis rate in the myocardium was 
determined by TUNEL according to the manufactur-
er’s  instructions  (Roche Applied  Science,  South  San 
Francisco,  California, USA).  Six  micrographs  were 
randomly  selected  and  the  numbers  of  healthy  or 
apoptotic  cardiomyocytes  were  counted.  The  per-
centage  of  apoptotic  cells  was  considered  the  per-
centage  of  the  total  numbers  of  cells  that 
TUNEL-positive. 
Primary culture of neonatal rat cardiac myo-
cytes  
Newborn  female  rats  (n  =  10)  were  steri-
lized with 75%  alcohol  and  euthanized.  The  hearts 
were removed and dipped into pre-cooled D-Hank’s 
solution. After washing 3X with D-Hank’s, the myo-
cardium  was  cut  into  one-millimeter  cubic  pieces. 
Tissues were then digested with 0.06% trypsin. After 
centrifugation, cells were resuspended with Dulbec-
co's modified Eagle's medium and Ham's F-12 nutri-
ent  mixture  (DMEM/F12)  supplemented  with  10% 
fetal bovine serum (FBS) and incubated in a humidi-
fied  atmosphere  with  5%  CO2  at  37°C  for  90  min. 
Cardiac myocytes were then purified by differential 
adhesion. Forty-eight hours later, cells were arrested 
in the G0 phase through 24 h of serum-free medium 
incubation. After that, cells were randomly assigned 
for four groups. In the control group (Cont), cells were 
maintained in DMEM/F12. In the atorvastatin treat-
ment  group  (Ator),  cells  were  treated  with  a  final 
concentration of 10-5 M atorvastatin. For Ang II stim-
ulation, cells were treated with 10-7 M Ang II,  with or 
without 10-5 M atorvastatin (Ang II + Ator and Ang II, 
respectively).  
Flow cytometry analysis 
Twenty-four  hours  after  drug  treatment,  cells 
were  harvested  and  adjusted  to  a  confluency  of 
0.5×106  to  1×106  cells/mL.  Subsequently,  cells  were 
fixed with 70% pre-colded alcohol and stained with 
propidium iodide (PI). PI-labeled cells were analyzed 
using flow cytometry.  
Western blot 
Total protein from myocardium tissues or cells 
were  extracted  and  separated  by  sodium  dodecyl 
sulfate-polyacrylamide  gel  electrophoresis 
(SDS-PAGE).  Proteins  were  then  transferred  to  a 
polyvinylidene difluoride (PVDF) membrane, blocked 
and  probed  sequentially  with  primary  antibodies 
against GRP78, caspase-12 and CHOP. After incuba-
tion in the primary antibody, the membrane was in-
cubated in an appropriate secondary antibody. After 
washing,  the  bound  antibody  complexes  were  de-
tected using an electrochemiluminescence reagent. 
Statistical analysis 
Statistical analyses were performed using SPSS 
10.0  software.  Data  were  presented  as  mean 
±standard deviation (SD). The difference between two 
groups was evaluated by un-paired t test. The differ-
ences  among  different  groups  were  determined  by 
Kruskal-Wallis test. A probability (P) - value of < 0.05 
was considered statistically significant.  
Results 
Atorvastatin suppressed heart failure after MI 
To investigate the roles of Atorvastatin in pro-
tecting  HF  after  MI, we  initially  examined  the  rat 
heart of different groups for morphological changes. Int. J. Med. Sci. 2011, 8 
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Eight weeks after LAD ligation, hearts from rats in the 
model group presented with abnormal enlarged ven-
tricular  cavity  (Fig.  1A).  Pathological  examination 
showed that the cardiac myocytes exhibited an irreg-
ular shape and arrangement with myocardial fibrosis. 
Moreover, the  number  of  cardiac  myocytes  was 
greatly  reduced.  Notably,  4  weeks  of  Atorvastatin 
treatment (atorvastatin treatment group) significantly 
suppressed the signs of HF in the MI animals (Fig. 
1A).  
 
 
Figure 1. Atorvastatin suppressed HF in the rat with MI (A) Representative images of hearts. Four weeks after drug ad-
ministration, the heart was removed, and tissue sections were stained with H&E or Masson's trichrome. Hemodynamic 
index, including ±dP/dtmax (B), LVEDP and LVSP (C), and the levels of plasma BNP (D) were recorded after the final dose. 
+dP/dtmax, maximal rate of rise in blood pressure in ventricular chamber; -dp/dtmax, maximal rate of declining in blood 
pressure in ventricular chamber; LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure. Data 
were presented as mean ± SD. 
*P < 0.05 compared with untreated MI model group. (×200 magnification) 
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Hemodynamic index was then compared among 
different groups. As shown in Figure 1, B and C, the 
untreated  model  group  had  increased  LVEDP,  but 
decreased  LVSP  and  ±  dP/dt  max.  ELISA  analysis 
showed that the plasma BNP level was promoted in 
the model group as compared with sham operation 
group. However, atorvastatin administration signifi-
cantly reduced the LVEDP and BNP levels, and ele-
vated LVSP and ± dP/dt max levels, compared to the 
untreated model (P < 0.05). These observations sug-
gested that atorvastatin protected against HF in rats 
with MI.  
Atorvastatin treatment inhibited apoptosis of 
myocardial cells after MI 
Cell apoptosis is one of the major outcomes of 
HF  after  MI,  which  indicates  the  molecular  mecha-
nism by which the lethality of HF is induced. The ob-
servations  that  atorvastatin  protected  against  HF  in 
rats with MI motivated us to further investigate the 
impacts of atorvastatin on myocardial cell apoptosis. 
With  the  TUNEL  assay,  we  found  that  increased 
number of apoptotic myocardial cells were presented 
in rats with MI induced by LAD ligation, whereas the 
atorvastatin  treatment  dramatically  decreased  cell 
apoptosis (Fig. 2).  
To further confirm this, we then used cultured 
rat  cardiac  myocytes  to  evaluate  the  effects  of 
atorvastatin. Twenty-four hours after Ang II stimula-
tion, elevated numbers of apoptotic cells labeled by PI 
staining  were  detected  as  revealed, as  revealed  by 
flow  cytometry  (Fig.  3).  Atorvastatin  greatly  sup-
pressed cell apoptosis induced by Ang II. Altogether, 
these results demonstrated that atorvastatin inhibited 
cell apoptosis in MI both in vivo and in vitro. 
 
 
 
Figure 2. Atorvastatin inhibited cell apoptosis in the rat with MI. TUNEL analysis was carried out four weeks after the end 
of drug treatments. (A) The TUNEL-positive cells (apoptotic cells) are indicated by arrows. (B) Quantification of apoptotic 
cell death. 
*P < 0.05 compared with untreated MI model group.  Int. J. Med. Sci. 2011, 8 
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Figure 3. Atorvastatin suppressed cell apoptosis in Ang II-stimulated cardiac myocytes. In the control group (Cont), cells 
were maintained in DMEM/F12 culture medium. In the atorvastatin treatment group (Ator), cells were incubated with 10
-5 
M atorvastatin. For Ang II stimulation, cells were treated with 10
-7 M Ang II and Ator (Ang II + Ator) or without 10
-5 M 
atorvastatin (Ang II). (A-D) Cell apoptosis was determined by flow cytometry 24 h after drug treatment. Quantified data are 
presented in (E). 
*P < 0.05 compared with the Ang II group; 
#P < 0.05 compared with the Cont group.  
 
 
Atorvastatin mediated myocardium protec-
tion by inhibiting ERSR 
The activation of the ERSR is one of the under-
lying  mechanisms  that  induce  cell  apoptosis  in  HF 
after MI. To establish the link between ERSR and the 
inhibition  of cell apoptosis induced by atorvastatin, 
we  examined  the  levels  of  important  proteins  in-
volved  in  ERSR  and  apoptosis.  Among  these, 
GRP78 is a protein of the ER lumen whose expression 
is  induced  during  ER stress  [16]. CHOP  has  been 
recognized to play a crucial role in regulating apop-
tosis  induced  by  ER  stress  [17], and  caspase-12  is 
required for the apoptotic pathway and contributes to 
ER stress-triggered caspase activation [18, 19]. 
 As  indicated  by  Fig.  4A-D,  elevated  levels  of 
GRP78,  CHOP  and  caspase-12  were  observed  in 
model group in vivo and in Ang II-stimulated cells in 
vitro.  However,  four  weeks  of  atorvastatin  admin-
istration  significantly  suppressed  all  these  protein 
levels, both  in  vivo  and  in  vitro.  Furthermore,  the 
GRP78  level  was  positively  correlated  with  the  cell 
apoptosis  rate  both  in  vivo  (r  =  0.97694,  P  <  0.05; 
Fig.4E)  and  in vitro  r  =  0.91578,  P  <  0.05; Fig.  4F). 
Collectively, these results demonstrated that the inhi-
bition of cell apoptosis induced by atorvastatin in HF 
after  MI  may  be  linked  to  the  suppression  of  the 
ERSR.  
 Int. J. Med. Sci. 2011, 8 
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Figure 4.  Atorvastatin mediated myocardium protection by inhibiting the ERSR. Protein extracted from myocardium 
tissues four weeks after drug administration (A) or cardiac myocytes 24 h after drug treatment (B) were separated and 
immunoblotted sequentially with anti-GRP78, -caspase-12 and CHOP antibodies. GAPDH was used as a control reference. 
Band intensity is quantified in (C) and (D). The correlation between apoptosis and GRP78 is presented in (E) and (F). *P < 
0.05 compared with Model or Ang II group;
 #P < 0.05 compared with sham operated (Sham) or control (Cont) group. 
 
Discussion 
A  variety  of  stimuli,  such  as hypoxia  [20,  21], 
oxidative stress [22], Ang II stimulation [12] and in-
flammatory factors [23], has been suggested to trigger 
ER stress during HF. The stressed ER induces the ac-
tivation of CHOP [23], JNK [24], and caspase-12 [25] 
and subsequently leads to cardiac myocytes apopto-
sis. There are evidences that the expressions of GRP78 
and  CHOP  are  markedly  induced  four  weeks  after 
transverse aortic constriction (TAC), accompanied by 
the  activation  of  apoptosis  [10].  Heart  failure  may 
induce the ERSR, the activated ERSR contributes to 
cell  apoptosis,  and  finally  apoptosis  promotes  the 
progression of HF [10].  
Consistent with previous studies, here we found 
elevated expressions of GRP78 and CHOP in vitro and 
in  vivo  MI  model,  suggesting  that  induction  of  ER 
stress  occurred  during  HF  after  MI.  Moreover,  the 
activation of ER stress coincided with the timing of Int. J. Med. Sci. 2011, 8 
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the  appearance  of  apoptosis.  Increased 
TUNEL-positive cells were detected under fluorescent 
microscope, and elevated numbers of PI-positive cells 
were found by flow cytometry during HF.  
In other studies, caspase-12, which is localized 
on the ER membrane, was specifically activated by ER 
stress [18, 19], and in another the cleavage of caspa-
se-12  was  not  observed  in  hearts  after  TAC  [10]. 
However, in the current study, the level of caspase-12 
was greatly increased during HF, suggesting the in-
volvement  of  caspase-12  in  ER  stress-triggered  cell 
apoptosis. This discrepancy may be due to differences 
in observed time points or the experimental model.  
Atorvastatin,  a  hydroxymethylglutaryl- 
coenzyme  A  reductase  inhibitor,  has  the  ability  to 
effectively  decrease  blood  lipids  and  may  provide 
some advantages over other statins [26]. The admin-
istration  of  atorvastatin  was  found  to  improve  left 
ventricular  ejection  fraction,  attenuated  adverse  left 
ventricular remodeling in patients with nonischemic 
HF [14], and depressed the inflammatory process in 
patients  with  HF  [15].  Nevertheless,  the  role  of 
atorvastatin in myocardial protection after MI is still 
poorly known.  
In this study, we found that 4 weeks of treatment 
with atorvastatin dramatically relieved heart failure, 
as  heart  morphology  was  unchanged  and  hemody-
namic indices were maintained in atorvastatin-treated 
rats.  Compared  with  the  model  group,  atorvastatin 
administration significantly reduced LVEDP and BNP 
levels, and elevated LVSP and ±dP/dtmax (P < 0.05). 
Moreover,  atorvastatin  decreased  the  cell  apoptosis 
rate  and  downregulated  the  expressions  of  GRP78, 
CHOP,  and  caspase-12  induced  by  LAD  ligation in 
vivo, and by Ang II stimulation in vitro. This suggests 
that the myocardial protective effects of atorvastatin 
were achieved by regulating the ERSR and apoptotic 
signal pathway.  
Although  the  induction  of  both  the  ERSR  and 
apoptosis was observed in the in vivo rat MI model 
and in the in vitro Ang II-stimulated cardiac myocyte 
model, the association between ERSR and apoptosis 
has not been fully demonstrated in this study. There 
have been reports that the ERSR led to cardiac myo-
cyte apoptosis during the progression of HF [10, 11]. 
Therefore, it is possible that the ERSR contributes to 
cell  apoptosis  in  cardiac  myocytes.  We  hypothesize 
that  atorvastatin  may  inhibit  the  activation  of  ER 
stress by downregulating GRP78 and CHOP expres-
sion, which subsequently suppresses the induction of 
apoptosis.  Therefore,  our  current  study  presents  a 
novel target for the prevention of MI-induced cardi-
omyocyte loss. Our future study will be focused on 
exploring the potential association between the ERSR 
and apoptosis activation during HF after MI. 
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